IMMUNITY TO S PNEUMONIAE VACCINE IN HIV-INFECTED AFRICAN-AMERICANS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。HIV感染的非洲裔美国成年人对肺炎链球菌荚膜多糖（血清型4、6 B、9V、14、18 C、19 F和23 F）的免疫力水平较低。目前推荐的23价肺炎球菌多糖疫苗对侵袭性肺炎球菌疾病没有很好的保护作用。在HIV感染的非洲裔美国成人中使用免疫原性更强的肺炎球菌七价结合疫苗的经验有限。我们的假设是，他们将有更高的免疫应答肺炎球菌结合疫苗（CPV）比肺炎球菌多糖疫苗（PPV）。具体目标; 1）检测黑人HIV感染者血清中肺炎链球菌（Streptococcuspneumoniae，PPS）4、6 B、9V、14、18 C、19 F和23 F型抗体水平; 2）调理吞噬试验（opsonophagocytic assay，OPA）检测功能性抗体应答; 4）将抗体水平与免疫学和病毒学参数相关联5）确定HIV感染成人对肺炎球菌结合七价疫苗（CPV）和23价肺炎球菌多糖疫苗（PPV）序贯接种与单剂量肺炎球菌多糖疫苗相比产生的免疫力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV infected African-American adults have low levels of immunity to Streptococcus pneumoniae capsular polysaccharide (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F). The currently recommended 23-valent pneumococcal polysaccharide vaccine does not offer very good protection against invasive pneumococcal disease. Experience with the more immunogenic conjugate pneumococcal heptavalent vaccine in HIV-infected African-American adults is limited. Our hypothesis is that they will have higher immune response to pneumococcal conjugate vaccine (CPV) than to pneumococcal polysaccharide vaccine (PPV). Specific Aims; 1) To determine antibody levels to serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F of Streptococcus pneumoniae capsular polysaccharide (PPS) in HIV-infected Blacks 2) To determine the functional antibody response by opsonophagocytic assay (OPA) 3) To determine the correlation between the patient serotype-specific immunity and S. pneumoniae serotype isolated from blood culture 4) To correlate antibody levels with immunologic and virologic parameters 5) To determine immunity generated in HIV-infected adults against sequential vaccination with conjugate pneumococcal heptavalent vaccine (CPV) and 23-valent pneumococcal polysaccharide vaccine (PPV) as compared with single-dose pneumococcal polysaccharide vaccine.